(Q34431985)

English

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer (English)

1 reference

Europe PubMed Central

2 August 2017

0 references

cost-effectiveness analysis

1 reference

based on heuristic

inferred from title

author name string

Malek B Hannouf

1

1 reference

Europe PubMed Central

2 August 2017

Bin Xie

2

1 reference

Europe PubMed Central

2 August 2017

Muriel Brackstone

3

1 reference

Europe PubMed Central

2 August 2017

Gregory S Zaric

4

1 reference

Europe PubMed Central

2 August 2017

language of work or name

0 references

publication date

2 October 2012

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

12

1 reference

Europe PubMed Central

2 August 2017

447

1 reference

Europe PubMed Central

2 August 2017

https://scigraph.springernature.com/pub.10.1186/1471-2407-12-447

0 references

Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Survival and treatment patterns in elderly patients with advanced non-small-cell lung cancer in Manitoba

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Adjuvant docetaxel for high-risk, node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Health economics in drug development: efficient research to inform healthcare funding decisions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Radiation treatment waiting times for breast cancer patients in Manitoba, 2001 and 2005.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Trial assessing individualized options for treatment for breast cancer: the TAILORx trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Economic evaluation of 21-gene reverse transcriptase-polymerase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Is molecular profiling ready for use in clinical decision making?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Canadian breast cancer guidelines: have they made a difference?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Economic evaluations in the canadian common drug review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Side effects of adjuvant treatment of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Systematic overview of cost-utility assessments in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

The relationship between prognostic and predictive factors in the management of breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Dollars may not buy as many QALYs as we think: a problem with defining quality-of-life adjustments.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Tentative guidelines for using clinical and economic evaluations revisited.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

6 July 2018

Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Histopathologic variables predict Oncotype DX recurrence score

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Markov models in medical decision making: a practical guide.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol I

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Should the elderly receive chemotherapy for node-negative breast cancer? A cost-effectiveness analysis examining total and active life-expectancy outcomes.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-12-447

21 January 2018

Breast cancer and prognostic factors. Tumour size, degree of differentiation, proliferation kinetics and expression of steroid hormone receptors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3488327

27 October 2018

Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23031196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/23031196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trends in breast cancer by race and ethnicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23031196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Amplification of c-erbB-2 and aggressive human breast tumors?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23031196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adjuvant systemic therapy for women with node-negative breast cancer. The Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23031196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The efficacy and cost-effectiveness of adjuvant therapy of early breast cancer in premenopausal women

1 reference

https://pubmed.ncbi.nlm.nih.gov/23031196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada

1 reference

https://pubmed.ncbi.nlm.nih.gov/23031196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health-care organization

1 reference

https://pubmed.ncbi.nlm.nih.gov/23031196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)

1 reference

https://pubmed.ncbi.nlm.nih.gov/23031196

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-12-447

1 reference

Europe PubMed Central

2 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 August 2017

1 reference

Europe PubMed Central

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34431985&oldid=1623146028"